PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 79 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2013. The put-call ratio across all filers is 44.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2017 | $3,538,000 | +69.5% | 521,025 | +135.7% | 0.00% | 0.0% |
Q1 2017 | $2,087,000 | +165.5% | 221,081 | +142.9% | 0.00% | – |
Q4 2016 | $786,000 | +400.6% | 91,035 | +152.2% | 0.00% | – |
Q1 2016 | $157,000 | -93.6% | 36,100 | -90.9% | 0.00% | -100.0% |
Q4 2015 | $2,438,000 | -49.9% | 397,773 | -53.3% | 0.00% | 0.0% |
Q3 2015 | $4,868,000 | -60.4% | 851,094 | -48.4% | 0.00% | -66.7% |
Q2 2015 | $12,303,000 | +39.2% | 1,649,287 | +11.6% | 0.00% | +50.0% |
Q1 2015 | $8,841,000 | -19.1% | 1,478,427 | +2.3% | 0.00% | -33.3% |
Q4 2014 | $10,929,000 | +39.8% | 1,445,677 | -4.0% | 0.00% | +50.0% |
Q3 2014 | $7,815,000 | +15.6% | 1,505,734 | -4.0% | 0.00% | 0.0% |
Q2 2014 | $6,762,000 | +7.0% | 1,569,104 | +1.5% | 0.00% | 0.0% |
Q1 2014 | $6,321,000 | +47.5% | 1,545,614 | +92.3% | 0.00% | +100.0% |
Q4 2013 | $4,284,000 | -3.6% | 803,734 | -9.0% | 0.00% | 0.0% |
Q3 2013 | $4,442,000 | -25.8% | 883,134 | -34.2% | 0.00% | -50.0% |
Q2 2013 | $5,986,000 | – | 1,342,204 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Phocas Financial Corp. | 1,033,328 | $6,376,000 | 0.68% |
ARDSLEY ADVISORY PARTNERS LP | 650,000 | $4,011,000 | 0.63% |
Worth Venture Partners, LLC | 138,357 | $853,000 | 0.47% |
RICE HALL JAMES & ASSOCIATES, LLC | 2,242,503 | $13,836,000 | 0.46% |
HIGHLAND CAPITAL MANAGEMENT LP | 716,880 | $4,423,000 | 0.26% |
FARALLON CAPITAL MANAGEMENT LLC | 5,543,386 | $34,203,000 | 0.22% |
Point72 Asset Management, L.P. | 5,858,749 | $36,148,000 | 0.19% |
PINNACLE ASSOCIATES LTD | 1,298,723 | $8,013,000 | 0.19% |
Fosun International Ltd | 472,580 | $2,750,000 | 0.18% |
J. Goldman & Co LP | 400,000 | $2,468,000 | 0.17% |